HUP0001108A2 - Stabil üvegállapotú porkiszerelések - Google Patents
Stabil üvegállapotú porkiszerelésekInfo
- Publication number
- HUP0001108A2 HUP0001108A2 HU0001108A HUP0001108A HUP0001108A2 HU P0001108 A2 HUP0001108 A2 HU P0001108A2 HU 0001108 A HU0001108 A HU 0001108A HU P0001108 A HUP0001108 A HU P0001108A HU P0001108 A2 HUP0001108 A2 HU P0001108A2
- Authority
- HU
- Hungary
- Prior art keywords
- composition
- matrix
- active substance
- powdered
- glass
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 3
- 239000011521 glass Substances 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 2
- 230000004888 barrier function Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 230000009477 glass transition Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012797 qualification Methods 0.000 abstract 1
- 229920001187 thermosetting polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A találmány pőrlasztőtt, stabil diszperzitással rendelkező összetételtbiztősít. Az összetétel jellemző üvegesedési hőmérséklettel (Tg) ésajánlőtt tárőlási hőmérséklettel (Ts) rendelkezik, ahől a Tg és a Tsközötti különbség legalább 10 řC (azaz a Tg-Ts nagyőbb mint 10 řC). Azösszetétel egy gyógyszerészetileg elfőgadható üveges mátrix éslegalább egy, az üveges mátrixban lévő, gyógyászatilag aktív anyagkeverékét tartalmazza. Tővábbá, egy pőrlasztőtt gyógyszerészetilegelfőgadható hőrdőzóval is keverhető. Különösen előnyös, ha azegységdózis főrma nedvességgátlót tartalmaz a megfelelő minősítésielőírásőkkal összhangban. A találmány a pőrlasztőtt diszperzibilisösszetétel előállítási eljárásról szintén gőndőskődik, ahől az eljárásaz őldószert, az üvegképzőt és a gyógyszerészetileg aktív anyagőttartalmazó őldatból az őldószer eltávőlítását tartalmazza őlyankörülménynek között, amely a mátrixban lévő gyógyszerészetileg aktívanyagőt tartalmazó üveges mátrix kialakításáhőz megfelel. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/733,225 US6258341B1 (en) | 1995-04-14 | 1996-10-17 | Stable glassy state powder formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001108A2 true HUP0001108A2 (hu) | 2000-08-28 |
HUP0001108A3 HUP0001108A3 (en) | 2000-11-28 |
Family
ID=24946736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001108A HUP0001108A3 (en) | 1996-10-17 | 1997-10-14 | Stable glassy state powder formulations |
Country Status (21)
Country | Link |
---|---|
US (1) | US6258341B1 (hu) |
EP (2) | EP0941067B1 (hu) |
CN (1) | CN1124843C (hu) |
AR (1) | AR013854A1 (hu) |
AT (1) | ATE245969T1 (hu) |
AU (1) | AU734891B2 (hu) |
CA (1) | CA2274758C (hu) |
CO (1) | CO5011099A1 (hu) |
DE (1) | DE69723854T2 (hu) |
DK (1) | DK0941067T3 (hu) |
EA (1) | EA002055B1 (hu) |
ES (1) | ES2203792T3 (hu) |
GE (1) | GEP20032985B (hu) |
HK (1) | HK1024618A1 (hu) |
HU (1) | HUP0001108A3 (hu) |
IL (1) | IL130476A (hu) |
NZ (1) | NZ336171A (hu) |
PT (1) | PT941067E (hu) |
TW (1) | TW504389B (hu) |
WO (1) | WO1998016205A2 (hu) |
ZA (1) | ZA979145B (hu) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
CA2231968A1 (en) * | 1998-03-11 | 1999-09-11 | Smoke-Stop, A Partnership Consisting Of Art Slutsky | Method of producing a nicotine medicament |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
US6234167B1 (en) | 1998-10-14 | 2001-05-22 | Chrysalis Technologies, Incorporated | Aerosol generator and methods of making and using an aerosol generator |
FR2787329B1 (fr) * | 1998-12-17 | 2001-02-09 | Aventis Pharma Sa | Nouvelle application therapeutique des heparines de bas poids moleculaire |
AU779869B2 (en) | 1999-04-13 | 2005-02-17 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
WO2001013891A2 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US7252840B1 (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles |
PT1666028E (pt) | 1999-10-29 | 2010-06-15 | Novartis Ag | Composições de pós anidros com melhor dispersividade |
JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
DK1280520T4 (en) | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0011807D0 (en) * | 2000-05-16 | 2000-07-05 | Quadrant Holdings Cambridge | Formulation for inhalation |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
EP1305040B1 (en) * | 2000-07-28 | 2009-09-09 | Christopher J. Murphy | Transplant media |
FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
WO2002015880A2 (en) * | 2000-08-25 | 2002-02-28 | Merck Patent Gmbh | Powdered mannitol and mannitol-containing compositions |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
US6799572B2 (en) | 2000-12-22 | 2004-10-05 | Chrysalis Technologies Incorporated | Disposable aerosol generator system and methods for administering the aerosol |
US6701921B2 (en) | 2000-12-22 | 2004-03-09 | Chrysalis Technologies Incorporated | Aerosol generator having heater in multilayered composite and method of use thereof |
US6501052B2 (en) | 2000-12-22 | 2002-12-31 | Chrysalis Technologies Incorporated | Aerosol generator having multiple heating zones and methods of use thereof |
US6491233B2 (en) | 2000-12-22 | 2002-12-10 | Chrysalis Technologies Incorporated | Vapor driven aerosol generator and method of use thereof |
US6681998B2 (en) | 2000-12-22 | 2004-01-27 | Chrysalis Technologies Incorporated | Aerosol generator having inductive heater and method of use thereof |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
HUP0400083A2 (hu) * | 2001-05-04 | 2004-04-28 | Pfizer Products Inc. | Aeroszol formájú inzulin alkalmazása 2 típusú diabetes megelőzésére |
WO2002094243A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US6640050B2 (en) | 2001-09-21 | 2003-10-28 | Chrysalis Technologies Incorporated | Fluid vaporizing device having controlled temperature profile heater/capillary tube |
US6568390B2 (en) | 2001-09-21 | 2003-05-27 | Chrysalis Technologies Incorporated | Dual capillary fluid vaporizing device |
US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
AU2002352836B2 (en) * | 2001-11-20 | 2005-09-29 | Alkermes, Inc. | Improved particulate compositions for pulmonary delivery |
AU2002346472A1 (en) * | 2001-11-20 | 2003-06-10 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US6681769B2 (en) | 2001-12-06 | 2004-01-27 | Crysalis Technologies Incorporated | Aerosol generator having a multiple path heater arrangement and method of use thereof |
US6804458B2 (en) | 2001-12-06 | 2004-10-12 | Chrysalis Technologies Incorporated | Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
US6701922B2 (en) | 2001-12-20 | 2004-03-09 | Chrysalis Technologies Incorporated | Mouthpiece entrainment airflow control for aerosol generators |
WO2003086443A1 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
WO2003087335A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
US7923029B2 (en) * | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
AU2003263024A1 (en) * | 2002-04-23 | 2003-11-10 | Christopher Mcconville | Process of forming and modifying particles and compositions produced thereby |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
JP2005530765A (ja) * | 2002-05-07 | 2005-10-13 | ネクター セラピューティクス | 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法 |
CA2508870C (en) | 2002-12-30 | 2012-10-16 | Nektar Therapeutics | Prefilming atomizer |
DE10306766A1 (de) * | 2003-02-18 | 2004-08-26 | Ino Therapeutics Gmbh | Dosierte Abgabe eines therapeutischen Gases |
CA2526478A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
JP2007500234A (ja) * | 2003-05-28 | 2007-01-11 | ネクター セラピューティクス | 水に不溶な活性剤を含む医薬的成形 |
EP1660661A2 (en) | 2003-08-08 | 2006-05-31 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
DE10339197A1 (de) * | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
CA2543482A1 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
AU2004288854B2 (en) * | 2003-11-10 | 2009-10-01 | Arriva-Pharmaceuticals, Inc. | Dry recombinant human alpha 1-antitrypsin formulation |
EP1701714A2 (en) * | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
RU2006141358A (ru) | 2004-04-23 | 2008-05-27 | Сайдекс, Инк. (Us) | Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина |
US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
DE102004022928A1 (de) * | 2004-05-10 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung |
US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
US7723306B2 (en) * | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
DE102004022926A1 (de) * | 2004-05-10 | 2005-12-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung |
EP2626368B1 (en) | 2004-07-19 | 2016-12-21 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
MX2007001611A (es) * | 2004-08-11 | 2007-04-10 | Cadbury Adams Usa Llc | Composiciones calidas y sistemas de liberacion de las mismas. |
EP1831373A2 (en) * | 2004-12-22 | 2007-09-12 | Novozymes A/S | Recombinant production of serum albumin |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
EP1973523A2 (en) * | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
GB0716026D0 (en) * | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
US8268354B2 (en) * | 2007-11-07 | 2012-09-18 | Aridis Pharmaceuticals | Sonic low pressure spray drying |
US20110105693A1 (en) * | 2008-05-01 | 2011-05-05 | Kanata Chemical Technologies Inc. | Cationic transition-metal arene catalysts |
US9827205B2 (en) * | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
AU2010229668C1 (en) | 2009-03-26 | 2016-09-15 | Pulmatrix Operating Co., Inc. | Dry powder formulations and methods for treating pulmonary diseases |
CA2763939A1 (en) * | 2009-05-29 | 2010-12-02 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
GB0918450D0 (en) * | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
US8758824B2 (en) | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
ES2899621T3 (es) | 2010-09-29 | 2022-03-14 | Pulmatrix Operating Co Inc | Polvos secos catiónicos que comprenden sal de magnesio |
RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
MX350838B (es) | 2011-02-11 | 2017-09-18 | Grain Proc Corporation * | Composicion de sal. |
CA2879317C (en) * | 2011-08-01 | 2019-01-15 | Monash University | Method and formulation for inhalation |
CN104023743B (zh) | 2011-10-25 | 2017-05-03 | 普罗西纳治疗有限公司 | 抗体制剂和方法 |
EP2790761B1 (en) | 2011-12-16 | 2022-05-11 | Novartis AG | Passive powder aerosolization apparatus |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
KR102391332B1 (ko) | 2013-03-15 | 2022-04-26 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
SG11201509543YA (en) | 2013-05-22 | 2015-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of three or more active agents |
US9688979B2 (en) | 2013-06-11 | 2017-06-27 | Biocartis Nv | Biomolecule drying process for long-term storage |
BR122019026637B1 (pt) * | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
JP6387094B2 (ja) * | 2013-11-22 | 2018-09-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 非ヌクレオシド逆転写酵素阻害剤の組成物 |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
AR102305A1 (es) | 2014-10-16 | 2017-02-15 | Teva Branded Pharmaceutical Products R&D Inc | Procedimiento para preparar formulación farmacéutica inhalable de polvo seco |
WO2016067252A1 (en) * | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
WO2016176552A1 (en) | 2015-04-30 | 2016-11-03 | Otitopic Inc. | Dry power formulations for inhalation |
CN108310560A (zh) * | 2015-05-16 | 2018-07-24 | 苏州汉方医药有限公司 | 一种药物器械组合成的用于治疗男性或女性功能低下的药盒 |
EP3532500A1 (en) | 2016-10-31 | 2019-09-04 | Vectura Limited | Inhalable powder composition comprising il-13 antibody |
WO2019222221A1 (en) * | 2018-05-14 | 2019-11-21 | Dance Biopharm Inc. | Insulin formulations for reconstitution into high concentration liquid solutions |
GB201817861D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Gel and crystalline powder |
CN113476428B (zh) * | 2021-01-28 | 2022-03-29 | 朗天药业(湖北)有限公司 | 一种吸入用硫酸沙丁胺醇溶液及其制备方法 |
CN112956693A (zh) * | 2021-02-26 | 2021-06-15 | 深圳大学 | 一种应急食品及其制备方法 |
IL309888A (en) | 2021-07-09 | 2024-03-01 | Astrazeneca Pharmaceuticals Lp | Aerosol drug delivery compounds, methods and systems |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
DE3682047D1 (de) | 1985-07-09 | 1991-11-21 | Quadrant Bioresources Ltd | Beschuetzung von proteinen und aehnlichem. |
GB8903593D0 (en) * | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
US5098955A (en) | 1989-09-18 | 1992-03-24 | Ppg Industries, Inc. | Powder coating composition low Tg and high Tg polymers with acid groups |
US5057392A (en) | 1990-08-06 | 1991-10-15 | Eastman Kodak Company | Low fusing temperature toner powder of cross-linked crystalline and amorphous polyester blends |
US5200399A (en) | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
JP2546089B2 (ja) * | 1991-07-09 | 1996-10-23 | 上村工業株式会社 | 錫又は半田めっき浴への金属イオン補給方法 |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
AU689217B2 (en) * | 1994-03-07 | 1998-03-26 | Novartis Ag | Methods and compositions for pulmonary delivery of insulin |
DE69534318T2 (de) * | 1994-05-18 | 2006-04-20 | Nektar Therapeutics, San Carlos | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen |
EP1516615A3 (en) * | 1994-08-04 | 2007-10-31 | Quadrant Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
DE69634246T2 (de) * | 1995-04-14 | 2006-01-12 | Nektar Therapeutics, San Carlos | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
GB9508691D0 (en) | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
US5826633A (en) | 1996-04-26 | 1998-10-27 | Inhale Therapeutic Systems | Powder filling systems, apparatus and methods |
-
1996
- 1996-10-17 US US08/733,225 patent/US6258341B1/en not_active Expired - Lifetime
-
1997
- 1997-10-13 ZA ZA9709145A patent/ZA979145B/xx unknown
- 1997-10-14 HU HU0001108A patent/HUP0001108A3/hu unknown
- 1997-10-14 CN CN97180736A patent/CN1124843C/zh not_active Expired - Fee Related
- 1997-10-14 PT PT97913707T patent/PT941067E/pt unknown
- 1997-10-14 AU AU50834/98A patent/AU734891B2/en not_active Ceased
- 1997-10-14 WO PCT/US1997/018901 patent/WO1998016205A2/en not_active Application Discontinuation
- 1997-10-14 EP EP97913707A patent/EP0941067B1/en not_active Revoked
- 1997-10-14 GE GEAP19974861A patent/GEP20032985B/en unknown
- 1997-10-14 IL IL13047697A patent/IL130476A/xx not_active IP Right Cessation
- 1997-10-14 AT AT97913707T patent/ATE245969T1/de not_active IP Right Cessation
- 1997-10-14 NZ NZ336171A patent/NZ336171A/en unknown
- 1997-10-14 DE DE69723854T patent/DE69723854T2/de not_active Revoked
- 1997-10-14 EP EP03013343A patent/EP1342469A3/en not_active Withdrawn
- 1997-10-14 EA EA199900454A patent/EA002055B1/ru not_active IP Right Cessation
- 1997-10-14 ES ES97913707T patent/ES2203792T3/es not_active Expired - Lifetime
- 1997-10-14 DK DK97913707T patent/DK0941067T3/da active
- 1997-10-14 CA CA002274758A patent/CA2274758C/en not_active Expired - Fee Related
- 1997-10-15 TW TW086115145A patent/TW504389B/zh not_active IP Right Cessation
- 1997-10-17 CO CO97061158A patent/CO5011099A1/es unknown
- 1997-10-17 AR ARP970104834A patent/AR013854A1/es not_active Application Discontinuation
-
2000
- 2000-03-15 HK HK00101575A patent/HK1024618A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1124843C (zh) | 2003-10-22 |
DE69723854T2 (de) | 2004-04-22 |
EP0941067A2 (en) | 1999-09-15 |
IL130476A (en) | 2005-05-17 |
IL130476A0 (en) | 2000-06-01 |
PT941067E (pt) | 2003-12-31 |
ES2203792T3 (es) | 2004-04-16 |
TW504389B (en) | 2002-10-01 |
EP1342469A3 (en) | 2004-01-21 |
AU5083498A (en) | 1998-05-11 |
EP0941067B1 (en) | 2003-07-30 |
ZA979145B (en) | 1998-05-11 |
ATE245969T1 (de) | 2003-08-15 |
NZ336171A (en) | 2001-06-29 |
CO5011099A1 (es) | 2001-02-28 |
WO1998016205A3 (en) | 1998-09-03 |
EA199900454A1 (ru) | 1999-12-29 |
US6258341B1 (en) | 2001-07-10 |
EP1342469A2 (en) | 2003-09-10 |
EA002055B1 (ru) | 2001-12-24 |
HUP0001108A3 (en) | 2000-11-28 |
DE69723854D1 (de) | 2003-09-04 |
HK1024618A1 (en) | 2000-10-20 |
CA2274758A1 (en) | 1998-04-23 |
WO1998016205A2 (en) | 1998-04-23 |
AR013854A1 (es) | 2001-01-31 |
AU734891B2 (en) | 2001-06-28 |
GEP20032985B (en) | 2003-06-25 |
DK0941067T3 (da) | 2003-11-17 |
CN1240349A (zh) | 2000-01-05 |
CA2274758C (en) | 2009-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001108A2 (hu) | Stabil üvegállapotú porkiszerelések | |
HUP9801615A2 (hu) | Szimetikon/vízmentes kalcium-foszfát-kompozíciók | |
SG64993G (en) | Slow-release pharmaceutical composition | |
IT1251153B (it) | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica | |
DK278288D0 (da) | Frigivelsessystem til laegemiddel ved anvendelse i mundhulen og en fremgangsmaade til fremstilling af dette frigivelsesystem | |
LT2000064A (en) | Flash-melt oral dosage formulation | |
AU1211992A (en) | Low dose dry pharmaceutical preparations | |
WO1995017156A3 (en) | Ethanol substitutes | |
IL86551A0 (en) | (1h-azol-1-ylmethyl)substituted benzotriazole derivatives,their preparation and pharmaceutical compositions containing them | |
CA2120133A1 (en) | Crystalline Amifostine Compositions and Methods for the Preparation and Use of Same | |
MY101847A (en) | Composition for solid pharmaceutical preparations of active vitamins d 3 and process for preparation thereof. | |
IL84446A0 (en) | 3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
IE40025B1 (en) | Hexahydro-dibenzo (b,d) pyran-9-ones as psychotropic or sedative drugs | |
MY101784A (en) | Novel pharmacological compounds | |
PL337794A1 (en) | Pharmaceutic agent for oral administration containing an active substance and cyclodextrin | |
HUP0002121A2 (hu) | Eljárás flurbiprofen gyógypasztillák előállítására | |
CA2316985A1 (en) | Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer | |
CA2271944A1 (en) | Formulation for electrically assisted delivery of lidocaine and epinephrine | |
AU1811688A (en) | Solid drug preparations containing micronized crystals of ebselen | |
CA2106216A1 (en) | Chewable antacid compositions | |
IL81179A0 (en) | Azine acid derivatives,their preparation and pharmaceutical compositions containing them | |
IL61207A0 (en) | Cytostatically active pharmaceutical compositions comprising isocyanuric acid derivatives, certain such novel derivatives and their preparation | |
AU2293488A (en) | Alkadiene derivatives, their preparation, and pharmaceutical compositions containing them | |
DE3070184D1 (en) | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | |
DE3068074D1 (en) | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |